{"title":"Combined JAK inhibition and PD-1 immunotherapy for non–small cell lung cancer patients | Science","link":"https://www.science.org/doi/10.1126/science.adf1329","date":1718974860000,"content":"Persistent inflammation driven by cytokines such as type-one interferon (IFN-I) can cause immunosuppression. We show that administration of the Janus kinase 1 (JAK1) inhibitor itacitinib after anti–PD-1 (programmed cell death protein 1) immunotherapy ...","author":"","siteTitle":"Science","siteHash":"08244134beaa7712a45a99601e5e0d25fd23f6384c4a65e503ee732006dc374e","entryHash":"489a06501cc2503ace49eeb7e596e2e70ef66880cc1453c024513350f752845d","category":"Interdisciplinary"}